|
Causative
Agent
Routes of Exposure
Toxic Dose
Incubation Period
Clinical Effects
Lethality
Transmissibility
Primary Contaminations &
Methods of Dissemination
Secondary Contamination &
Persistence of organism
Decontamination &
Isolation
Personal Protective
Equipment
Health Care Facility
Identification of
Exposure
Laboratory testing
Therapeutic Treatment
Prophylactic Treatment
Differential Diagnosis
References
Causative
Agent:
Tricothecene mycotoxins (T-2 mycotoxins) are
nonvolatile compounds produced by filamentous fungi primarily
of the genera Fusarium, Myrotecium,
Trichoderma, and Stachybotrys.
Routes of Exposure:
Inhalation, Dermal, and Oral.
Toxic Dose:
Inhalation – Unknown.
Dermal
– Unknown.
Oral
– Leukopenia seen with as little as 0.1mg/kg/day for several
weeks.
Incubation Period:
Inhalation
– Minutes
Dermal
– Minutes to hours
Oral
– Minutes to days
Clinical Effects:
Mycotoxins act by inhibition of protein synthesis.
Symptoms start within minutes to hours after exposure, and
involve eyes, skin, respiratory and gastrointestinal tracts.
-
Eyes
– Eye pain, excessive lacrimation, visual blurring and
scleral injection.
-
Inhalation
– Nasal itching and pain, epistaxis, rhinorrhea, cough,
dyspnea, wheezing.
-
Dermal
– Burning skin, redness, blistering progressing to necrosis,
skin sloughing.
-
Oral
– Anorexia, mouth pain, nausea, vomiting, hematemesis,
abdominal pain, watery or bloody diarrhea, abdominal cramps.
-
Early
systemic effects
– Weakness, loss of coordination, dizziness, ataxia,
tachycardia, hypothermia, hypotension or death.
-
Late
systemic effects
– Two to eight weeks after ingestion on contaminated food,
bone marrow suppression occurs with with severe neutropenia
and hemorrhagic syndromes such as diffuse bleeding into skin
with petechiae, melena, hematuria, hematemesis, epistaxis,
and vaginal bleeding. Other common problems include
fever, oral and GI ulceration, and secondary sepsis.
These effects are similar to the effects seen with exposure
to radiation.
Lethality: There is a
death rate of 10-20% with ingestion of contaminated food.
Transmissibility:
Person-to-person transmission of intoxication does not occur,
although exposure could occur by contact with contaminated
objects and surfaces that had not bee appropriately
decontaminated.
Primary dissemination:
There were reports that mycotoxins may have
been used in the past as bioterrorism weapons in Iran and
Southeast Asia. These were described as aerosol attacks in the form of “yellow rain”
with droplets of yellow fluid contaminating clothes and the
environment.
Secondary Contamination:
There is no person-to-person transmission but
contaminated fomites, such as clothing, could be a source of
exposure.
Decontamination &
Isolation:
-
Patients
– Outer clothing should be removed and exposed skin
decontaminated by washing thoroughly with soap and water.
Eye exposure should be treated with copious saline or water
irrigation. Once decontamination is complete, isolation is
not required.
-
Equipment,
clothing & other objects
– T-2 mycotoxins are stable in the environment, resistant to
heat and ultraviolet light. Environmental decontamination requires the
use of a chlorine bleach solution under alkaline conditions
such as a 1% sodium hypochlorite (1 part bleach + 4 parts
water) and 0.1M sodium hydroxide solution with one hour
contact time.
Personal Protective
Equipment:
Respiratory,
skin and eye protection are required since toxin can be
absorbed by the respiratory, gastrointestinal, dermal and
ocular routes.
Health Care Facility: There is no person-to-person transmission.
However, avoid contact with contaminated clothing. If a
contaminated person arrives fully clothed, protective clothing
should be worn until decontamination of the patient is
completed and contaminated clothing discarded.
Identification of
Exposure: Exposure to
T-2 mycotoxins should be suspected if an aerosol attack occurs
in the form of “yellow rain”. Currently, there are
no commercially available rapid field diagnostic tests
available. Confirmation requires testing of blood,
tissue, and environmental samples using gas liquid
chromatography-mass spectrometry techniques.
Laboratory testing:
Serum, nasopharyngeal swab, and urine can be sent for toxin.
Therapeutic Treatment:
Superactivated charcoal should be administered
to persons who may have ingested T-2 mycotoxins in order to
adsorb the toxin. There is no vaccine and no specific
antidote or therapeutic regimen. Treatment is
symptomatic and supportive.
Prophylactic Treatment:
None
Differential Diagnosis:
Mustard gas has a delay of several hours before
symptoms start. Staphylococcus enterotoxin B can cause
fever, cough, dyspnea and wheezing but does not involve the
skin. Ricin can cause severe respiratory distress, and
gastrointestinal symptoms, but does not involve the skin.
References:
-
Chin J.
Control of Communicable Diseases Manual, Seventeenth
Edition, American Public Health Association; 2000.
-
Kortepeter
M, Christopher G, Cieslak T, et al. Medical Management of
Biological Casualties Handbook, U.S. Army Medical Research
Institute of Infectious Diseases, U.S. Department of
Defense; 2001: 78-85
-
Wannemacher RW, Wiener SL. Trichothecene Mycotoxins. In:
Zajtchuk R, Bellamy RF, eds. Medical Aspects of Chemical and
Biological Warfare. Washington, DC: Office of the Surgeon
General, U.S. Department of the Army; 1997: 655-676.
-
Wortmann
G. Ricin Toxin. In: Physician’s Guide to Terrorist Attack.
Roy MJ, ed. Physician’s Guide to Terrorist Attack. Totowa,
NJ: Humana Press, Inc.; 2004:175-179
For more
information call (602) 364-3289 |